Neutralizing antibody of Interferon beta on multiple sclerosis (Multi-center clinical studies)

Neutralizing antibody of Interferon beta on multiple sclerosis (Multi-center clinical studies) - Neutralizing antibody of IFN-beta on MS (Multi-center clinical studies)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008186

Enrollment

100

Registered

2012-07-01

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis

Interventions

Blood for analysis (10ml) Term of analysis is from January 13, 2012 to March 31, 2016. Frequency of analysis is a time or two.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Among MS patients during IFN -beta treatment, the group of patients that the IFN-beta neutralizing antibody is useful

Exclusion criteria

Exclusion criteria: Not MS patients

Design outcomes

Primary

Measure	Time frame
To analyze the frequency of neutralizing antibody positive of interferon beta	—

Countries

Japan

Contacts

Public ContactDouglas Sato

Tohoku University Graduate School of Medicine Department of Multiple Sclerosis Therapeutics

nab@neurol.med.tohoku.ac.jp022-717-7190

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026